To the Editor We read with interest the report by Wortelboer et al evaluating sequencing strategies for cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6) inhibitors in hormone receptor–positive, ERBB2-negative advanced breast cancer. The authors concluded that delayed introduction of CDK4/6 inhibitors after initial endocrine therapy did not compromise overall survival (OS) compared with first-line use. While the SONIA trial provides important evidence regarding treatment sequencing, several aspects of the statistical framework warrant further clarification.
Классификация: Наука| # | Наименование новости | Тональность | Информативность | дата |
|---|---|---|---|---|
| 1 | Survival in the SONIA Trial | 0 | 0 | 18-06-2026 |
| 2 | Survival in the SONIA Trial—Reply | 0 | 0 | 18-06-2026 |
| 3 | Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer | 0 | 0 | 18-06-2026 |
| 4 | Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy | 0 | 0 | 18-06-2026 |
| 5 | Further Methodological and Clinical Reflections | 0 | 0 | 11-06-2026 |
| 6 | Скворцова заявила, что рост показателя общей смертности от рака удалось стабилизировать | 0 | 0 | 25-09-2019 |
| 7 | Error in Open Access License | 0 | 0 | 18-06-2026 |
| 8 | Повышение мощности новосибирского синхротрона может сорвать сроки его строительства | 0 | 0 | 11-09-2019 |
| 9 | Exercise may help protect older adults against cancer | 0 | 0 | 17-06-2026 |
| 10 | Оказывать помощь онкобольным будут по-новому: новосибирцам объяснили суть изменений | 0 | 0 | 20-05-2026 |
